Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.

ABSTRACT: Assessment of measurable residual disease (often referred to as "minimal residual disease") has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in chronic lymphocytic leukemia. Undetectable-measurable residual disease status at the end of treatment demonstrated independent prognostic significance in chronic lymphocytic leukemia, correlating with favorable progression-free and overall survival with chemoimmunotherapy. Given its utility in evaluating depth of response, determining measurable residual disease status is now a focus of outcomes in chronic lymphocytic leukemia clinical trials. Increased adoption of measurable residual disease assessment calls for standards for nomenclature and outcom

SUBMITTER: Wierda WG 

PROVIDER: S-EPMC8550962 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature